GleamWall
中文EN

LFVN Lifevantage Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 849146 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-24.8%
TTM net income YoY-73.1%
TTM EPS YoY-73.1%
Revenue 3-yr CAGR-6.9%
Net income 3-yr CAGR2.1%

Margins

Gross margin76.5%
Operating margin2.1%
Net margin1.6%
FCF margin5.1%
EBITDA margin3.8%

Returns

ROE8.2%
ROA4.5%
ROIC (approx.)14.0%
Asset turnover2.85x

Leverage & solvency

Liabilities / assets43.8%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income4.81x
Accruals ratio-17.2%
Payout ratio88.2%
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30
Income statement
Revenue$182.59M$228.53M
Cost of revenue$40.97M$44.86M
Gross profit$141.61M$183.67M
R&D expense$1.00M$1.40M
SG&A expense$58.42M$69.21M
Operating income$6.10M$12.20M
Pretax income$6.07M$12.24M
Income tax$994,000$2.44M
Net income$5.07M$9.80M
EBITDA$8.87M$15.36M
EPS (basic)0.400.80
EPS (diluted)0.400.75
Dividends declared per share0.180.17
Weighted avg. shares (diluted)12.70M12.99M
Balance sheet
Cash & equivalents$14.92M$20.20M
Receivables$2.99M$3.29M
Inventory$16.17M$20.67M
Current assets$38.30M$50.89M
PP&E, net$7.31M$6.21M
Goodwill$465,000$0
Intangibles$3.06M$245,000
Total assets$62.11M$71.96M
Current liabilities$20.23M$27.22M
Total liabilities$28.52M$37.32M
Shareholders' equity$33.59M$34.64M
Shares outstanding12.52M12.43M
Cash flow statement
Operating cash flow$10.24M$11.88M
Capital expenditure$3.57M$1.37M
Free cash flow$6.67M$10.51M
Investing cash flow-$7.31M-$1.37M
Financing cash flow-$7.78M-$7.60M
Depreciation & amortization$2.77M$3.16M
Stock-based compensation$2.35M$5.70M
Dividends paid$2.34M$2.07M
Share buybacks$2.04M$3.15M

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.